Dogwood Therapeutics enters ATM equity distribution agreement to sell up to $8.6M of common stock

Dogwood Therapeutics, Inc.

Agreement with Northland Securities to sell up to $8,558,712 of common stock via at-the-market offerings.
Amount represents 21.38% of the value of outstanding common stock held by non-affiliates.
Sales agent commission: 3.0% of gross proceeds from shares sold under the agreement.
Shares will be issued under effective shelf registration (File No. 333-287575) and a prospectus supplement dated Nov 28, 2025.
Agreement includes customary representations, warranties, indemnification, and termination provisions.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Dogwood Therapeutics, Inc. entered into Equity Distribution Agreement with Northland Securities, Inc. (trade name Northland Capital Markets) valued at up to $8,558,712 (effective 2025-11-28).

Action: entry
Agreement: atm program
Counterparty: Northland Securities, Inc. (trade name Northland Capital Markets)
Value: up to $8,558,712
Effective: 2025-11-28

Exact text from the filing

On November 28, 2025, Dogwood Therapeutics, Inc., a Delaware corporation (the “Company”), entered into an Equity Distribution Agreement (the “Agreement”) with Northland Securities, Inc. (trade name Northland Capital Markets), as sales agent (the “Sales Agent”), relating to the issuance and sale from time to time by the Company (the “ATM Program”), through the Sales Agent, of shares of the Company’s common stock, par value $0.0001 per share, having an aggregate offering price of up to $8,558,712 (the “Shares”).

View on SEC.gov

Browse all material agreements →

Dogwood Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-25-116865

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.